Despite Regeneron Pharmaceuticals’ underperformance relative to the broader market over the past year, Wall Street analysts maintain a bullish outlook about the stock’s prospects.

The Significance of Analyst Ratings Explained Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems.

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

On Friday, Bernstein SocGen Group revised its price target for Regeneron (NASDAQ:REGN) Pharmaceuticals (NASDAQ: REGN) to $1,000 from the previous $1,070, while retaining an Outperform rating on ...

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Regeneron's Dupixent leads growth as Eylea sales decline and valuation is attractive, but growth is delayed by 2-3 years. Learn more on REGN stock here.

On Tuesday, UBS analysts reaffirmed their Neutral rating for Regeneron Pharma stock (NASDAQ: NASDAQ:REGN), maintaining a price target of $633.00. The decision follows recent developments in ...

Regeneron Pharmaceuticals, Inc. (REGN) is a leading American biotechnology company headquartered in Tarrytown, New York. Valued at $52.9 billion by market cap, the company focuses on discovering ...

This was the stock's fourth consecutive day of gains.